(Q36264209)

13 August 2017

1 reference

title

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies (English)

1 reference

13 August 2017

4

Thierry Facon

1 reference

13 August 2017

1

Heinz Ludwig

1 reference

13 August 2017

David Khayat

2

1 reference

13 August 2017

Giuseppe Giaccone

series ordinal

3

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

104

1 reference

13 August 2017

issue

9

1 reference

13 August 2017

page(s)

1794-1807

1 reference

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

Proteasome inhibitors as therapeutic agents: current and future strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

The proteasome: structure, function, and role in the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

The proteasome: a novel target for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Involvement of the proteasome in various degradative processes in mammalian cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

The proteasome and MHC class I antigen processing

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Biological significance and molecular mechanisms of p53-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Development of the proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

NF-kappaB in cancer: from innocent bystander to major culprit

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Phase I study of bortezomib in refractory or relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21414

7 January 2021

Identifiers

DOI

10.1002/CNCR.21414

1 reference

13 August 2017

1 reference